TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03590730

Intervention type: DEVICE
Intervention: ICD implantation
Description: ICD will be implanted according to current guidelines recommendations.
Study: NCT02667210

Intervention type: OTHER
Intervention: Medical Record Review
Description: Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction

Intervention type: OTHER
Intervention: Medical Record Review
Description: Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction

Intervention type: OTHER
Intervention: Medical Record Review
Description: Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction

Intervention type: OTHER
Intervention: Medical Record Review
Description: Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction
Study: NCT03846986

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apple Juice1
Description: Apple Juice1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Juice2
Description: 100% Apple Juice with enzyme-treated apple pomace fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Raw Apple
Description: Raw Apple
Study: NCT00509067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP-choline
Description: CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Description: All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Description: All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
Study: NCT00574288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Daratumumab
Description: First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Daratumumab
Description: In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.~Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.~Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
Study: NCT04243850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Jardiance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Jardiance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: caffeine iv to investigate wheter the changes in renal hemodynamics are adenosine dependent

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: caffeine iv to investigate wheter the changes in renal hemodynamics are adenosine dependent
Study: NCT02772640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin and Ezetimibe morning or evening administration
Description: Timing of the drug administration:~morning -\> evening evening -\> morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin and Ezetimibe morning or evening administration
Description: Timing of the drug administration:~morning -\> evening evening -\> morning
Study: NCT03963414

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab in combination with carboplatin and etoposide
Description: 1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with carboplatin and etoposide
Description: 1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.
Study: NCT02056054

Intervention type: OTHER
Intervention: Pediatric transplant subject with d-AIH
Description: 30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.

Intervention type: OTHER
Intervention: Pediatric transplant subject with acute rejection
Description: Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.

Intervention type: OTHER
Intervention: Pediatric transplant subject with chronic rejection
Description: Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.

Intervention type: OTHER
Intervention: Adult non-transplant patients with auto-immune hepatitis
Description: 75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.~The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.~Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media.

Intervention type: OTHER
Intervention: Adult non-transplant subjects with chronic hepatitis C virus
Description: For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media.

Intervention type: OTHER
Intervention: Pediatric control subjects
Description: 2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.

Intervention type: OTHER
Intervention: Adult transplanted subjects with de novo autoimmune hepatitis
Description: 75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
Study: NCT01531322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
Study: NCT04048265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
Study: NCT04239105

Intervention type: DEVICE
Intervention: Microfluidic and Raman spectrum
Description: Detection of Circulating Tumor Cells
Study: NCT02284620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CFNB group
Description: CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LWI group
Description: LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
Study: NCT03364582

Intervention type: OTHER
Intervention: Observed dietary pattern
Description: No intervention will be used. This is an observational study with dietary patterns as main exposure

Intervention type: OTHER
Intervention: Observed dietary pattern
Description: No intervention will be used. This is an observational study with dietary patterns as main exposure
Study: NCT03039166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 7T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 7T

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI 7T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 7T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 7T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 7T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3 T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3 T

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI 3 T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3 T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3 T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3 T

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study: NCT02207998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathic complex and physiotherapy
Description: Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and physiotherapy
Description: Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
Study: NCT01733966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secnidazole, ciprofloxacine
Description: 2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Clavulanic Acid
Description: 3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
Study: NCT00097773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin solution for inhalation (TOBI)
Description: Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobramycin solution for inhalation (TOBI)
Description: Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin solution for inhalation (TOBI)
Description: Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobramycin solution for inhalation (TOBI)
Description: Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ciprofloxacin
Description: Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ciprofloxacin
Description: Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
Study: NCT01023867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: from 5mg to 10mg, once a day, 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: from 5mg to 10mg, once a day, 12 months
Study: NCT03924336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced- platelets rich fibrin (A-PRF+) + Open flap debridement (OFD)
Description: Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded , A-PRF+ of the required size will be filled into the intraosseous defect. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD) alone
Description: Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded. After debridement and intraoperative recordings, interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
Study: NCT00780819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoleStar N20 intraoperative MRI
Description: low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
Study: NCT04032704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladiratuzumab vedotin
Description: Intravenous (into the vein; IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladiratuzumab vedotin
Description: Intravenous (into the vein; IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladiratuzumab vedotin
Description: Intravenous (into the vein; IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladiratuzumab vedotin
Description: Intravenous (into the vein; IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladiratuzumab vedotin
Description: Intravenous (into the vein; IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg given by IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg given by IV on Day 1 of each 21-day cycle
Study: NCT01408433

Intervention type: OTHER
Group type: OTHER
Intervention: Single Embryo Transfer
Description: single embryo transfer of a chromosomally normal embryo

Intervention type: OTHER
Group type: OTHER
Intervention: Double embryo transfer
Description: two (2) embryo transfer of untested embryos
Study: NCT01186900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided needle aspiration
Description: one time drainage at time of randomization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided needle aspiration
Description: one time drainage at time of randomization
Study: NCT01249820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anidulafungin 200 mg q48h
Description: Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anidulafungin 300 mg q72h
Description: Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
Study: NCT03388242

Intervention type: OTHER
Intervention: No intervention
Description: Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.

Intervention type: OTHER
Intervention: No intervention
Description: Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.

Intervention type: OTHER
Intervention: No intervention
Description: Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.
Study: NCT05956730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity (AUD)
Description: Home training of patients with severe low vision managed through audio-guides (AUD).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity (SUP)
Description: Training of patients with severe low vision in a gym supervised by a personal trainer (SUP).